EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes

Domenico Larobina, Giorgia Franzino iD, Fabiana Tescione iD, Michela Abrami, Domenico Tierno, Alice Biasin iD, Federica Tonon, Anna De Nes iD, Marta Maggisano, Paola Confalonieri, Annalucia Carbone, Marco Confalonieri iD und 4 weitere

Pharmaceuticals · 27.04.2026 · 19 (5) · 681

DOI: 10.3390/ph19050681 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 27.04.2026. Verfasst von Domenico Larobina und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Polymers, Composites and Biomaterials, National Research Council of Italy, P. le E. Fermi 1, I-80055 Portici, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 245 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of University and Research, Regione Autonoma Friuli Venezia Giulia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Muco-obstructive lung diseases, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and bronchiectasis, are characterized by the accumulation of highly viscoelastic mucus that compromises mucociliary clearance and fosters infection and inflammation. Mucoactive therapy, encompassing both true mucolytics and non-cleaving agents, seeks to restore airway patency by altering mucus structure, hydration, and transport properties, yet its clinical impact remains variable. This narrative review provides a critical reappraisal of the pharmacological actions and therapeutic outcomes of the main mucolytic agents: N-acetylcysteine (NAC), erdosteine, carbocisteine, bromhexine, ambroxol, and dornase alfa. Beyond their classical role in reducing mucus viscosity, these drugs exhibit pleiotropic effects, including antioxidant, anti-inflammatory, and immunomodulatory activities. Specifically, for thiol-based compounds, the action consists of breaking the disulfide bonds that stabilize the mucin network; for carbocisteine, it lies in modulating mucin glycosylation and chloride transport. Ambroxol and bromhexine act by stimulating surfactant secretion and enhancing mucociliary clearance. Finally, dornase alfa exerts an enzymatic effect on extracellular DNA, a key contributor to the tenacity of mucus in cystic fibrosis. Clinical evidence indicates that NAC and erdosteine can reduce exacerbation rates in COPD, carbocisteine shows benefit with prolonged administration, and dornase alfa remains a cornerstone in CF management. However, therapeutic efficacy is constrained by heterogeneous mucus composition, pharmacokinetic limitations, and disease-specific variability. A key interpretative message is that clinical benefit appears greatest when the dominant biophysical determinant of mucus pathology is specifically targeted, supporting a transition from broad disease-label prescribing to mechanism-informed, phenotype-aware mucolytic therapy. Emerging strategies, such as agents targeting mucin–DNA interactions and advanced inhalation delivery systems, promise improved specificity and durability. By integrating mechanistic insights with clinical data, this review underscores the need for personalized mucolytic therapy and innovative approaches to overcome current challenges in managing muco-obstructive lung diseases.

Schlagwörter

Stichwörter der Autor:innen

airway mucusanti-inflammatory agentsmuco-obstructive lung diseasesmucoactive agentsoxidative stress

Autor:innen und Institutionen

  • Institute of Polymers, Composites and Biomaterials, National Research Council of Italy, P. le E. Fermi 1, I-80055 Portici, Italy.
  • Department of Engineering and Architecture, University of Trieste, Via Valerio 6/A, I-34127 Trieste, Italy.
  • Department of Medicine, Surgery and Health Sciences, University of Trieste, Strada di Fiume 447, I-34149 Trieste, Italy.
  • Pulmonology Unit, Department of Medical Surgical and Health Sciences, Hospital of Cattinara, University of Trieste, I-34149 Trieste, Italy.
  • Department of Clinical and Experimental Medicine, University of Foggia, I-71122 Foggia, Italy.

ORCID-Profile: Giorgia Franzino, Fabiana Tescione, Alice Biasin, Anna De Nes, Marco Confalonieri, Gabriele Grassi, Sante Di Gioia, Mario Grassi, Massimo Conese

Förderung

  • Italian Ministry of University and Research
  • Regione Autonoma Friuli Venezia Giulia

Zitieren

APA

Larobina, D., Franzino, G., Tescione, F., Abrami, M., Tierno, D., Biasin, A., Tonon, F., De Nes, A., Maggisano, M., Confalonieri, P., Carbone, A., Confalonieri, M., Grassi, G., Di Gioia, S., Grassi, M., & Conese, M. (2026). Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes. Pharmaceuticals, 19(5), 681. https://doi.org/10.3390/ph19050681

Vancouver

Larobina D, Franzino G, Tescione F, Abrami M, Tierno D, Biasin A, et al. Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes. Pharmaceuticals. 2026;19(5):681. doi:10.3390/ph19050681

BibTeX
@article{Larobina2026,
  author = {Larobina, Domenico and Franzino, Giorgia and Tescione, Fabiana and Abrami, Michela and Tierno, Domenico and Biasin, Alice and Tonon, Federica and De Nes, Anna and Maggisano, Marta and Confalonieri, Paola and Carbone, Annalucia and Confalonieri, Marco and Grassi, Gabriele and Di Gioia, Sante and Grassi, Mario and Conese, Massimo},
  title = {Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {5},
  pages = {681},
  doi = {10.3390/ph19050681}
}
Kostenlos starten →